SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Meta Expands AI Training With Employee Activity Tracking Tools 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
PHILADELPHIA, March 02, 2016 -- Spark Therapeutics (NASDAQ:ONCE) today announced that it will host a conference call on Wednesday, March 9, 2016 at 8:30 a.m. Eastern to report corporate and financial results for the year ended December 31, 2015.
The call can be accessed by dialing (855) 851-4526 (domestic) or (720) 634-2901 (international), and entering passcode 58251343. To access a live audio webcast, please visit the “Investors” section at www.sparktx.com.
A replay of the call will be available for one week following the call and can be accessed by dialing (855) 859-2056 (domestic) or (404) 537-3406 (international), and entering passcode 58251343 or also available on our website.
About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on two decades of research, development and manufacturing at The Children’s Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com.
Contacts Investor Relations Spark Therapeutics, Inc. Stephen W. Webster Chief Financial Officer (855) SPARKTX (1-855-772-7589) Media Ten Bridge Communications Dan Quinn (781) 475-7974 [email protected]
